Efficacy of pentoxifylline-tocopherol-clodronate in mandibular osteoradionecrosis.
Aged
Aged, 80 and over
Bone Density Conservation Agents
/ therapeutic use
Clodronic Acid
/ therapeutic use
Drug Combinations
Female
Humans
Male
Mandibular Diseases
/ drug therapy
Middle Aged
Osteoradionecrosis
/ drug therapy
Pentoxifylline
/ therapeutic use
Prospective Studies
Tocopherols
/ therapeutic use
Treatment Outcome
Osteoradionecrosis
clodronate
mandible
pentoxifylline
tocopherol
Journal
The Laryngoscope
ISSN: 1531-4995
Titre abrégé: Laryngoscope
Pays: United States
ID NLM: 8607378
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
24
06
2019
revised:
18
10
2019
accepted:
21
10
2019
pubmed:
21
11
2019
medline:
2
1
2021
entrez:
21
11
2019
Statut:
ppublish
Résumé
PENTOCLO treatment, associating pentoxifylline, tocopherol, and clodronate, resolves radiation-induced fibrosis. The main aim of the present study was to prospectively assess efficacy in mandibular osteoradionecrosis (ORN). Prospective cohort study. Twenty-seven patients with mandibular ORN were included in the Pentoclauvergne Study between January 2014 and February 2016. After an initial 28-day phase of antibiotic, antifungal, and corticosteroid therapy, they received the PENTOCLO association daily until cure or a maximum of 24 months. The main assessment criterion was exposed bone area (EBA); secondary criteria comprised the Subjective, objective, management, and analytic (SOMA) score. Under PENTOCLO, EBA decreased by 28% at 2 months, 55% at 6 months, and 92% at 24 months; the SOMA score decreased by 23%, 38%, and 50%, respectively. A complete treatment course cured 76.5% of patients at a mean 9.6 months. PENTOCLO is a simple, well-tolerated, and effective treatment for mandibular ORN. 4 Laryngoscope, 130:E559-E566, 2020.
Substances chimiques
Bone Density Conservation Agents
0
Drug Combinations
0
pentoxifylline-tocopherol-clodronate
0
Clodronic Acid
0813BZ6866
Tocopherols
R0ZB2556P8
Pentoxifylline
SD6QCT3TSU
Types de publication
Evaluation Study
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
E559-E566Informations de copyright
© 2019 The American Laryngological, Rhinological and Otological Society, Inc.
Références
Harris M. The conservative management of osteoradionecrosis of the mandible with ultrasound therapy. Br J Oral Maxillofac Surg 1992;30:313-318.
Epstein JB, Wong FL, Stevenson-Moore P. Osteoradionecrosis: clinical experience and a proposal for classification. J Oral Maxillofac Surg 1987;45:104-110.
Thorn JJ, Hansen HS, Specht L, Bastholt L. Osteoradionecrosis of the jaws: clinical characteristics and relation to the field of irradiation. J Oral Maxillofac Surg 2000;58:1088-1093; discussion 1093-1095.
Dhanda J, Pasquier D, Newman L, Shaw R. Current concepts in osteoradionecrosis after head and neck radiotherapy. Clin Oncol 2016;28:459-466.
Delanian S, Lefaix JL. Mature bone radionecrosis: from recent physiopathological knowledge to an innovative therapeutic action. Cancer Radiother J 2002;6:1-9.
Marx RE, Johnson RP. Studies in the radiobiology of osteoradionecrosis and their clinical significance. Oral Surg Oral Med Oral Pathol 1987;64:379-390.
Delanian S, Depondt J, Lefaix J-L. Major healing of refractory mandible osteoradionecrosis after treatment combining pentoxifylline and tocopherol: a phase II trial. Head Neck 2005;27:114-123.
Delanian S, Porcher R, Rudant J, Lefaix J-L. Kinetics of response to long-term treatment combining pentoxifylline and tocopherol in patients with superficial radiation-induced fibrosis. J Clin Oncol 2005;23:8570-8579.
D'Souza J, Lowe D, Rogers SN. Changing trends and the role of medical management on the outcome of patients treated for osteoradionecrosis of the mandible: experience from a regional head and neck unit. Br J Oral Maxillofac Surg 2014;52:356-362.
Costa DA, Costa TP, Netto EC, et al. New perspectives on the conservative management of osteoradionecrosis of the mandible: a literature review. Head Neck 2016;38:1708-1716.
Nadella KR, Kodali RM, Guttikonda LK, Jonnalagadda A. Osteoradionecrosis of the jaws: clinico-therapeutic management: a literature review and update. J Maxillofac Oral Surg 2015;14:891-901.
Myers RA, Marx RE. Use of hyperbaric oxygen in postradiation head and neck surgery. NCI Monogr 1990;(9):151-157.
Annane D, Depondt J, Aubert P, et al. Hyperbaric oxygen therapy for radionecrosis of the jaw: a randomized, placebo-controlled, double-blind trial from the ORN96 study group. J Clin Oncol 2004;22:4893-4900.
Wong JK, Wood RE, McLean M. Conservative management of osteoradionecrosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997;84:16-21.
Sanger JR, Matloub HS, Yousif NJ, Larson DL. Management of osteoradionecrosis of the mandible. Clin Plast Surg 1993;20:517-530.
Jeyaraj P, Bandyopadhyay TK. Diagnostic features and management strategy of a refractory case of osteoradionecrosis of the mandible: case report and review of literature. J Maxillofac Oral Surg 2016;15:256-267.
Jacobson AS, Zevallos J, Smith M, et al. Quality of life after management of advanced osteoradionecrosis of the mandible. Int J Oral Maxillofac Surg 2013;42:1121-1128.
Meyer I. Infectious diseases of the jaws. J Oral Surg 1970;28:17-26.
Marx RE. A new concept in the treatment of osteoradionecrosis. J Oral Maxillofac Surg 1983;41:351-357.
Delanian S, Lefaix J-L. Current management for late normal tissue injury: radiation-induced fibrosis and necrosis. Semin Radiat Oncol 2007;17:99-107.
Samlaska CP, Winfield EA. Pentoxifylline. J Am Acad Dermatol 1994;30:603-621.
Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J Clin Invest 1996;97:2692-2696.
Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-534.
McCaul JA. Pharmacologic modalities in the treatment of osteoradionecrosis of the jaw. Oral Maxillofac Surg Clin North Am 2014;26:247-252.
Delanian S. Striking regression of radiation-induced fibrosis by a combination of pentoxifylline and tocopherol. Br J Radiol 1998;71:892-894.
Delanian S, Balla-Mekias S, Lefaix JL. Striking regression of chronic radiotherapy damage in a clinical trial of combined pentoxifylline and tocopherol. J Clin Oncol 1999;17:3283-3290.
Hayashi M, Pellecer M, Chung E, Sung E. The efficacy of pentoxifylline/tocopherol combination in the treatment of osteoradionecrosis. Spec Care Dentist 2015;35:268-271.
Delanian S, Chatel C, Porcher R, Depondt J, Lefaix J-L. Complete restoration of refractory mandibular osteoradionecrosis by prolonged treatment with a pentoxifylline-tocopherol-clodronate combination (PENTOCLO): a phase II trial. Int J Radiat Oncol Biol Phys 2011;80:832-839.
Delanian S, Lefaix J-L. Complete healing of severe osteoradionecrosis with treatment combining pentoxifylline, tocopherol and clodronate. Br J Radiol 2002;75:467-469.
Delanian S, Lefaix J-L. The radiation-induced fibroatrophic process: therapeutic perspective via the antioxidant pathway. Radiother Oncol J Eur Soc Ther Radiol Oncol 2004;73:119-131.
Pavy JJ, Denekamp J, Letschert J, et al.; EORTC Late Effects Working Group. Late effects toxicity scoring: the SOMA scale. Radiother Oncol J Eur Soc Ther Radiol Oncol 1995;35:11-15.
Robard L, Louis M-Y, Blanchard D, Babin E, Delanian S. Medical treatment of osteoradionecrosis of the mandible by PENTOCLO: preliminary results. Eur Ann Otorhinolaryngol Head Neck Dis 2014;131:333-338.
Patel V, Gadiwalla Y, Sassoon I, Sproat C, Kwok J, McGurk M. Use of pentoxifylline and tocopherol in the management of osteoradionecrosis. Br J Oral Maxillofac Surg 2016;54:342-345.
Epstein MS, Wicknick FW, Epstein JB, Berenson JR, Gorsky M. Management of bisphosphonate-associated osteonecrosis: pentoxifylline and tocopherol in addition to antimicrobial therapy. An initial case series. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010;110:593-596.
Owosho AA, Estilo CL, Huryn JM, Yom SK. Pentoxifylline and tocopherol in the management of cancer patients with medication-related osteonecrosis of the jaw: an observational retrospective study of initial case series. Oral Surg Oral Med Oral Pathol Oral Radiol 2016;122:455-459.
Hansen T, Kunkel M, Kirkpatrick CJ, Weber A. Actinomyces in infected osteoradionecrosis-underestimated? Hum Pathol 2006;37:61-67.
Hansen T, Kunkel M, Springer E, et al. Actinomycosis of the jaws-histopathological study of 45 patients shows significant involvement in bisphosphonate-associated osteonecrosis and infected osteoradionecrosis. Virchows Arch Int J Pathol 2007;451:1009-1017.
Ben-David MA, Diamante M, Radawski JD, et al. Lack of osteoradionecrosis of the mandible after intensity-modulated radiotherapy for head and neck cancer: likely contributions of both dental care and improved dose distributions. Int J Radiat Oncol Biol Phys 2007;68:396-402.
Beech NM, Porceddu S, Batstone MD. Radiotherapy-associated dental extractions and osteoradionecrosis. Head Neck 2017;39:128-132.
Duarte VM, Liu YF, Rafizadeh S, Tajima T, Nabili V, Wang MB. Comparison of dental health of patients with head and neck cancer receiving IMRT vs conventional radiation. Otolaryngol Head Neck Surg 2014;150:81-86.
Patel V, Gadiwalla Y, Sassoon I, Sproat C, Kwok J, McGurk M. Prophylactic use of pentoxifylline and tocopherol in patients who require dental extractions after radiotherapy for cancer of the head and neck. Br J Oral Maxillofac Surg 2016;54:547-550.